Joshua Pertman
Medical · Baltimore, MDNPI 1225781917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 271 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$863
- Dexcom, Inc.$781
- Novo Nordisk$606
- Amgen$523
- Corcept Therapeutics$441
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $1,146 |
| AstraZeneca | 34 | $863 |
| Dexcom, Inc. | 18 | $781 |
| Novo Nordisk | 30 | $606 |
| Amgen(2 entities) | 29 | $523 |
| Corcept Therapeutics | 13 | $441 |
| Lilly USA, LLC | 21 | $434 |
| Bayer | 8 | $338 |
| Merck | 11 | $254 |
| Pfizer | 13 | $230 |
| Boehringer Ingelheim | 5 | $129 |
| Xeris Pharmaceuticals, Inc. | 1 | $113 |
| Neurocrine Biosciences, Inc. | 4 | $107 |
| Sumitomo Pharma America, Inc. | 4 | $107 |
| Johnson & Johnson | 5 | $95 |
| Averitas Pharma Inc. | 3 | $81 |
| Exact Sciences | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Organogenesis Inc. | 2 | $36 |
| AbbVie | 2 | $34 |
| Astellas Pharma US Inc | 1 | $31 |
| Biomarin Pharmaceutical Inc. | 1 | $27 |
| UCB, Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$384
- AREXVY$242
- Kerendia$150
- Korlym$146
- TEZSPIRE$135
- AIRSUPRA$125
- GVOKE HYPOPEN$113
- KRYSTEXXA$110
- DEXCOM G7 GSS (161)$107
How this compares
$6,681 in reported general payments places this provider in the 85th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $84,012 |
| FarxigaDapagliflozin Propanediol | 48 | $55,170 |
| EliquisApixaban | 54 | $52,821 |
| OzempicSemaglutide | 39 | $52,149 |
| RybelsusSemaglutide | 11 | $26,884 |
| JardianceEmpagliflozin | 14 | $20,071 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $17,809 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $15,944 |
| GemtesaVibegron | 12 | $12,591 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $6,866 |
| Diclofenac Sodium | 28 | $4,940 |
| Atorvastatin Calcium | 312 | $2,653 |
| Lidocaine | 12 | $2,176 |
| Gabapentin | 74 | $2,127 |
| Fluticasone Propionate | 105 | $1,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,146 | $84,01264 claims |
| Novo NordiskOzempic, Rybelsus | $606 | $79,03350 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $863 | $71,11468 claims |
| PfizerEliquis | $230 | $52,82154 claims |
| Boehringer IngelheimJardiance | $129 | $20,07114 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $41 | $17,80919 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $12,59112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 medical providers in Maryland.
Other medical in Baltimore
- Sarah SagorskyBaltimore$68K
- Maribeth HatalskiBaltimore$11K
- Edward MikulaBaltimore$11K
- Natalie OrbachBaltimore$10K
- Helen ReidlerBaltimore$10K
- Michelle DanielsBaltimore$9K
- Chana AbramsBaltimore$7K
- Victoria TrottStevensville$94K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.